
Talazoparib/Enzalutamide Combo, Radioligand Therapy Expand Options in mCRPC
In the second part of an interview with OncLive®, Marc R. Matrana, MD, discussed the evolving role of molecular profiling in treatment selection for patients with prostate cancer; the clinical implications of the phase 3 TALAPRO-2 trial (NCT03395197) …